DENALI THERAPEUTICS INC (DNLI) — insider trading
Health Care · NASDAQ
DENALI THERAPEUTICS INC (DNLI) has 20 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 20 (latest 2026-06-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Cook Jennifer E. | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Cook Jennifer E. | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Van Hauwermeiren Timothy | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Van Hauwermeiren Timothy | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Thornberry Nancy | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Thornberry Nancy | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Schenkein David P | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Schenkein David P | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Krognes Steve E. | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Krognes Steve E. | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Klein Peter S | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Klein Peter S | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-06-03 | FLATLEY JAY T | Director | Grant / award / vesting (derivative) | 19,226 | $0.00 | $0 | Form 4 |
| 2026-06-03 | FLATLEY JAY T | Director | Grant / award / vesting | 6,408 | $0.00 | $0 | Form 4 |
| 2026-01-06 | Schuth Alexander O. | Officer (COFO and Secretary) | Open-market sale | 17,218 | $16.50 | $284.1K | Form 4 |
| 2026-01-06 | Watts Ryan J. | Director, Officer (President and CEO) | Open-market sale | 35,198 | $16.50 | $580.8K | Form 4 |
Ask the chat about DNLI's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DENALI THERAPEUTICS INC (DNLI).
Last updated 2026-06-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.